therapy related acute myeloid leukemia and myelodysplastic syndrome
therapy related acute myeloid leukemia and myelodysplastic syndrome
Explore linked clinical trials. Standard reference: MONDO:001945722 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Not yet recruiting | Phase 2 | 2026-10-01 | NCT05554419 | |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, chronic myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, myeloproliferative neoplasm, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 1 | 2026-09-18 | NCT03630991 | |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, leukemia, myelodysplastic syndrome with excess blasts-1, myelodysplastic syndrome with excess blasts-2, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, primary myelofibrosis, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 1 | 2026-09-18 | NCT02530034 | |
| Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-09-16 | NCT05807932 | |
| Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 1 | 2026-09-11 | NCT01861314 | |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 1 | 2026-09-09 | NCT02890329 | |
| Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, acute biphenotypic leukemia, acute myeloid leukemia, adult acute lymphoblastic leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, myeloid leukemia, neoplasm, skin disorder, skin neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 1 | 2026-08-26 | NCT02159495 | |
| A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 1 | 2026-08-25 | NCT05886049 | |
| BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 2 | 2026-08-03 | NCT04284787 | |
| Personalized NK Cell Therapy in CBT | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute biphenotypic leukemia, acute myeloid leukemia, anemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 2 | 2026-07-30 | NCT02727803 | |
| A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 1 | 2026-07-20 | NCT07250646 | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, myelodysplastic syndrome, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 1 | 2026-07-06 | NCT05139004 | |
| Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Leukemia, Myelomonocytic, Acute, Myeloproliferative Disorders, Neoplasms by Histologic Type, acute erythroid leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, adult acute monocytic leukemia, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 2 | 2026-07-01 | NCT00658814 | |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 2 | 2026-06-12 | NCT04214249 | |
| Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 1 | 2026-06-11 | NCT03041688 | |
| Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 2 | 2026-05-20 | NCT03747757 | |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute biphenotypic leukemia, acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, myelodysplastic syndrome, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 2 | 2026-05-20 | NCT02115295 | |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute biphenotypic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, mixed phenotype acute leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-05-15 | NCT06928662 | |
| Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Leukemia, Myelomonocytic, Acute, Neoplasms by Histologic Type, acute basophilic leukemia, acute monocytic leukemia, acute myeloid leukemia, adult acute monocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 2 | 2026-04-27 | NCT01627041 | |
| CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 1 | 2026-03-05 | NCT05672147 | |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Bone Marrow Failure Disorders, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Hodgkins lymphoma, Immunoglobulin Light-chain Amyloidosis, Infections, Leukemia, B-Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myeloid, Chronic-Phase, Lymphadenopathy, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, MALT lymphoma, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, acquired polycythemia vera, acute biphenotypic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, amyloidosis, anaplastic large cell lymphoma, anemia, angioimmunoblastic T-cell lymphoma, aplastic anemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, cytomegalovirus infection, diffuse large B-cell lymphoma, essential thrombocythemia, extramedullary plasmacytoma, follicular lymphoma, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, intraocular lymphoma, large-cell immunoblastic lymphoma, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, mast cell leukemia, mastocytosis, metabolic disease, monoclonal gammopathy, mycosis fungoides, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, nodal marginal zone B-cell lymphoma, ocular cancer, plasma cell neoplasm, post-transplant lymphoproliferative disease, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, prolymphocytic leukemia, proteostasis deficiencies, refractory hairy cell leukemia, solitary osseous plasmacytoma, splenic marginal zone lymphoma, therapy related acute myeloid leukemia and myelodysplastic syndrome, thrombocytosis disease, vascular disorder, vascular hemostatic disease, viral infectious disease | Active, not recruiting | Not stated | 2026-01-28 | NCT01199562 | |
| Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2022-10-18 | NCT05584761 |